You are here

  • Home
  • Archive
  • Volume 65, Issue 11
  • Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort

Citation Tools

Article menu

This article has a correction. Please see:

Download PDFPDF

XML
Hepatology
Original article
Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Welzel TM, Petersen J, Herzer K, et al
Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort
Gut 2016;65:1861-1870.